What are the management options for pulmonary embolism?

Pulmonary Embolism Management

Risk Stratification: The Critical First Step

All patients with suspected PE should be immediately risk-stratified based on hemodynamic stability, as this determines the entire treatment pathway and directly impacts mortality. 1, 2

High-Risk PE (Massive PE)

• Defined by cardiogenic shock and/or persistent arterial hypotension (systolic BP <90 mmHg or drop ≥40 mmHg for >15 minutes) 3, 1
• Characterized by collapse/hypotension with unexplained hypoxia, engorged neck veins, and often right ventricular gallop 3
• Carries the highest early mortality risk and requires immediate aggressive intervention 3

Intermediate-Risk PE (Submassive PE)

• Hemodynamically stable but with evidence of right ventricular dysfunction on imaging or elevated cardiac biomarkers (troponin, BNP/NT-proBNP) 3, 1
• Represents a gray zone where treatment escalation may be needed if clinical deterioration occurs 2

Low-Risk PE

• Hemodynamically stable without right ventricular dysfunction 1
• PESI class I/II, sPESI 0, or meeting Hestia criteria 3
• Candidates for outpatient management if no exclusion criteria present 3

---

Management Algorithm by Risk Category

HIGH-RISK PE: Immediate Life-Saving Interventions

Systemic thrombolysis is the first-line treatment for high-risk PE and should be administered immediately unless absolute contraindications exist. 3, 1, 2

Immediate Actions (within minutes):

1. Start IV unfractionated heparin immediately without waiting for confirmatory imaging—do not use LMWH or fondaparinux in this setting as they have not been tested in shock 3, 4
2. Administer oxygen to correct hypoxemia 3, 4
3. Correct systemic hypotension with vasopressors (norepinephrine, isoproterenol, or epinephrine preferred) 3, 5
4. Avoid aggressive fluid challenge—this worsens right ventricular failure; consider preload reduction or gentle diuresis instead 3, 5

Thrombolytic Therapy:

• Alteplase 100 mg IV over 90 minutes (accelerated MI regimen) is the standard dose 3, 2
• Alternative: Alteplase 50 mg IV bolus in cardiac arrest or rapidly deteriorating patients 3
• Reassess at 30 minutes; dramatic hemodynamic improvement should occur 3
• Resume unfractionated heparin 3 hours after thrombolysis completion, preferably weight-adjusted 3, 2
• Contraindications to thrombolysis should be ignored in immediately life-threatening PE—the mortality benefit outweighs bleeding risk 3

When Thrombolysis Fails or is Contraindicated:

• Surgical pulmonary embolectomy via median sternotomy with normothermic cardiopulmonary bypass is the recommended alternative 3, 2
• Avoid aortic cross-clamping and cardioplegic arrest unless intracardiac thrombi or patent foramen ovale present 3
• Catheter embolectomy or fragmentation may be considered when surgery unavailable, though evidence is limited 3

---

INTERMEDIATE-RISK PE: Anticoagulation with Selective Escalation

Immediate anticoagulation is mandatory, but routine thrombolysis is not recommended—reserve it only for clinical deterioration. 3, 1, 2

Initial Management:

• Start LMWH or fondaparinux (preferred over unfractionated heparin in hemodynamically stable patients) 4, 2
• Monitor closely for signs of deterioration (worsening hypoxemia, hypotension, rising troponin/BNP) 3
• If RV dilatation identified on CT/echo with elevated biomarkers, consider inpatient admission for observation even if otherwise low-risk 3

Escalation Criteria:

• Rescue thrombolysis if hemodynamic deterioration occurs during hospitalization 3, 2
• One trial showed reduced need for emergency thrombolysis with upfront rtPA, but overall mortality was unchanged—thus routine use remains controversial 3

---

LOW-RISK PE: Anticoagulation ± Outpatient Management

Low-risk patients should be started on anticoagulation and considered for outpatient management where robust pathways exist. 3, 1

Outpatient Eligibility (must meet ALL criteria):

• PESI class I/II, sPESI 0, or Hestia criteria met 3
• Oxygen saturation ≥90% on room air 3
• Heart rate <110 bpm, systolic BP ≥100 mmHg 3
• No severe pain requiring opiates 3
• No active bleeding risk, recent GI bleed/surgery, or uncontrolled hypertension 3
• Not on full-dose anticoagulation at time of PE 3
• eGFR ≥30 mL/min (CKD stages 1-3) 3
• Adequate social support and ability to return for follow-up 3

---

Anticoagulation Strategy: The Foundation of All PE Treatment

Initial Anticoagulation (First 5-21 Days)

For hemodynamically stable patients, NOACs with single-drug approaches (rivaroxaban or apixaban) are preferred as they eliminate the need for parenteral bridging. 1, 2, 6

NOAC Regimens (Preferred):

• Rivaroxaban: 15 mg PO twice daily with food for 21 days, then 20 mg once daily with food 2, 6
• Apixaban: 10 mg PO twice daily for 7 days, then 5 mg twice daily 2
• Edoxaban or dabigatran: Require 5 days of parenteral anticoagulation (LMWH/fondaparinux) before starting 1

Alternative: LMWH/Fondaparinux Bridged to Warfarin:

• LMWH or fondaparinux for minimum 5 days overlapping with warfarin until INR 2.0-3.0 (target 2.5) for 2 consecutive days 2, 7
• Use when NOACs contraindicated (severe renal impairment CrCl <15 mL/min, antiphospholipid antibody syndrome) 1, 6

High-Risk Patients:

• IV unfractionated heparin only—LMWH and fondaparinux not validated in shock 3, 4

---

Duration of Anticoagulation

Minimum 3 months for all patients, with consideration for extended or indefinite therapy based on recurrence risk. 1, 2, 8

Provoked PE (surgery, trauma, estrogen):

• 3 months if transient reversible risk factor 1

Unprovoked PE or Persistent Risk Factors:

• Consider indefinite anticoagulation due to heightened recurrence risk after cessation, especially given DOAC safety profile 8
• Reassess risk-benefit at 3-6 months 1, 2

Cancer-Associated PE:

• Traditionally LMWH preferred, though NOACs increasingly used 9

---

Special Populations

Pregnancy:

• Fixed-dose LMWH based on early pregnancy weight is treatment of choice 2
• CTPA is safe (fetal radiation <50 mSv) and preferred over V/Q scan in first/second trimester 1
• Avoid spinal/epidural procedures within 24 hours of last LMWH dose 2

Severe Renal Impairment (CrCl <30 mL/min):

• Avoid rivaroxaban 6
• Consider dose-adjusted warfarin or reduced-dose apixaban (if CrCl 15-29 mL/min) 6

IVC Filters:

• Not recommended for routine use 1, 2
• Consider only with absolute contraindications to anticoagulation AND high VTE recurrence risk 1, 2

---

Follow-Up and Long-Term Complications

All patients require routine re-evaluation at 3-6 months post-PE to assess for chronic thromboembolic pulmonary hypertension (CTEPH). 4, 1, 2

• Implement integrated care model for optimal hospital-to-ambulatory transition 4, 1
• Refer to pulmonary hypertension expert center if persistent dyspnea or mismatched perfusion defects on V/Q scan beyond 3 months 4, 1
• CTEPH is rare but carries significant morbidity and mortality 8

---

Critical Pitfalls to Avoid

• Never delay anticoagulation while awaiting diagnostic confirmation in high clinical probability patients 1, 2
• Never use LMWH/fondaparinux in hemodynamically unstable patients—only IV unfractionated heparin 3, 4
• Never give aggressive fluid boluses in massive PE—this worsens RV failure 3, 5
• Never withhold thrombolysis in life-threatening PE due to relative contraindications—mortality benefit outweighs bleeding risk 3
• Never perform neuraxial procedures within 24 hours of LMWH due to spinal hematoma risk 2, 6